Serological levels of mutated p53 protein are highly detected at early stages in breast cancer patients

Autores
Balogh, Gabriela Andrea; Mailo, Daniel; Nardi, Héctor; Corte, María Marta; Vincent, Esteban; Barutta, Elena; Lizarraga, Guillermo; Lizarraga, Pablo; Montero, Héctor; Gentili, Roberto; Mordoh, Jose
Año de publicación
2010
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
The aim of this study was to compare the sensitivity of the serological level of anti-p53 antibodies in breast cancer patients and to correlate its expression level with patient age, histological stage and grade of tumor differentiation. Total p53 protein expression (mutant and wild-type) was also determined in the breast cancer tissues using immunohistochemistry (IHC). The serological levels of mutant p53 expression were found to be age-dependent, reaching the highest level at 50 years of age. Faint or low detection was observed in patients ≤30 years of age. Anti-p53-antibodies were detected in patients ≤40 and ≥61 years of age. The serological levels of mutant p53 protein were highly detected in all stages of breast cancer, including the early stages. However, anti-p53 antibodies reached a high level of detection only in stage III breast carcinomas. No expression was found in patients with benign breast disease. The detection of p53 mutations was dependent on the grade of tumor differentiation, achieving the highest level in the poorly differentiated breast carcinomas. Results from IHC were highly correlated with serological p53 mutational analysis. Our findings indicate that mutant p53 in serum is a promising novel parameter for the evaluation of cellular biology and the prognosis of breast cancer from its early stages using blood samples. Anti-p53 antibodies were demonstrated to be less sensitive in this study. It is also possible to use the expression of mutant p53 protein as a molecular marker to differentiate benign breast disease from breast carcinoma prior to surgery.
Fil: Balogh, Gabriela Andrea. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Bahía Blanca. Centro de Recursos Naturales Renovables de la Zona Semiarida. Universidad Nacional del Sur. Centro de Recursos Naturales Renovables de la Zona Semiarida; Argentina
Fil: Mailo, Daniel. No especifíca;
Fil: Nardi, Héctor. No especifíca;
Fil: Corte, María Marta. No especifíca;
Fil: Vincent, Esteban. No especifíca;
Fil: Barutta, Elena. No especifíca;
Fil: Lizarraga, Guillermo. No especifíca;
Fil: Lizarraga, Pablo. No especifíca;
Fil: Montero, Héctor. No especifíca;
Fil: Gentili, Roberto. No especifíca;
Fil: Mordoh, Jose. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Pque. Centenario. Instituto de Investigaciones Bioquímicas de Buenos Aires. Fundación Instituto Leloir. Instituto de Investigaciones Bioquímicas de Buenos Aires; Argentina
Materia
BREAST CANCER
P53 MUTATIONAL ANALYSIS
SEROLOGICAL DETECTION OF P53 MUTATIONS
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/16134
Acceder
id CONICETDig_eb003ba9fb30f23d11f867d29b8fe162
oai_identifier_str oai:ri.conicet.gov.ar:11336/16134
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Serological levels of mutated p53 protein are highly detected at early stages in breast cancer patientsBalogh, Gabriela AndreaMailo, DanielNardi, HéctorCorte, María MartaVincent, EstebanBarutta, ElenaLizarraga, GuillermoLizarraga, PabloMontero, HéctorGentili, RobertoMordoh, JoseBREAST CANCERP53 MUTATIONAL ANALYSISSEROLOGICAL DETECTION OF P53 MUTATIONShttps://purl.org/becyt/ford/1.6https://purl.org/becyt/ford/1The aim of this study was to compare the sensitivity of the serological level of anti-p53 antibodies in breast cancer patients and to correlate its expression level with patient age, histological stage and grade of tumor differentiation. Total p53 protein expression (mutant and wild-type) was also determined in the breast cancer tissues using immunohistochemistry (IHC). The serological levels of mutant p53 expression were found to be age-dependent, reaching the highest level at 50 years of age. Faint or low detection was observed in patients ≤30 years of age. Anti-p53-antibodies were detected in patients ≤40 and ≥61 years of age. The serological levels of mutant p53 protein were highly detected in all stages of breast cancer, including the early stages. However, anti-p53 antibodies reached a high level of detection only in stage III breast carcinomas. No expression was found in patients with benign breast disease. The detection of p53 mutations was dependent on the grade of tumor differentiation, achieving the highest level in the poorly differentiated breast carcinomas. Results from IHC were highly correlated with serological p53 mutational analysis. Our findings indicate that mutant p53 in serum is a promising novel parameter for the evaluation of cellular biology and the prognosis of breast cancer from its early stages using blood samples. Anti-p53 antibodies were demonstrated to be less sensitive in this study. It is also possible to use the expression of mutant p53 protein as a molecular marker to differentiate benign breast disease from breast carcinoma prior to surgery.Fil: Balogh, Gabriela Andrea. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Bahía Blanca. Centro de Recursos Naturales Renovables de la Zona Semiarida. Universidad Nacional del Sur. Centro de Recursos Naturales Renovables de la Zona Semiarida; ArgentinaFil: Mailo, Daniel. No especifíca;Fil: Nardi, Héctor. No especifíca;Fil: Corte, María Marta. No especifíca;Fil: Vincent, Esteban. No especifíca;Fil: Barutta, Elena. No especifíca;Fil: Lizarraga, Guillermo. No especifíca;Fil: Lizarraga, Pablo. No especifíca;Fil: Montero, Héctor. No especifíca;Fil: Gentili, Roberto. No especifíca;Fil: Mordoh, Jose. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Pque. Centenario. Instituto de Investigaciones Bioquímicas de Buenos Aires. Fundación Instituto Leloir. Instituto de Investigaciones Bioquímicas de Buenos Aires; ArgentinaSpandidos Publ Ltd2010-03-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/mswordapplication/pdfhttp://hdl.handle.net/11336/16134Balogh, Gabriela Andrea; Mailo, Daniel; Nardi, Héctor; Corte, María Marta; Vincent, Esteban; et al.; Serological levels of mutated p53 protein are highly detected at early stages in breast cancer patients; Spandidos Publ Ltd; Experimental and Therapeutic Medicine; 1; 2; 1-3-2010; 357-3611792-09811792-1015enginfo:eu-repo/semantics/altIdentifier/doi/DOI:10.3892/etm_00000056info:eu-repo/semantics/altIdentifier/url/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3445953/info:eu-repo/semantics/altIdentifier/url/https://www.spandidos-publications.com/etm/1/2/357info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-10T13:22:14Zoai:ri.conicet.gov.ar:11336/16134instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-10 13:22:14.747CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Serological levels of mutated p53 protein are highly detected at early stages in breast cancer patients
title Serological levels of mutated p53 protein are highly detected at early stages in breast cancer patients
spellingShingle Serological levels of mutated p53 protein are highly detected at early stages in breast cancer patients
Balogh, Gabriela Andrea
BREAST CANCER
P53 MUTATIONAL ANALYSIS
SEROLOGICAL DETECTION OF P53 MUTATIONS
title_short Serological levels of mutated p53 protein are highly detected at early stages in breast cancer patients
title_full Serological levels of mutated p53 protein are highly detected at early stages in breast cancer patients
title_fullStr Serological levels of mutated p53 protein are highly detected at early stages in breast cancer patients
title_full_unstemmed Serological levels of mutated p53 protein are highly detected at early stages in breast cancer patients
title_sort Serological levels of mutated p53 protein are highly detected at early stages in breast cancer patients
dc.creator.none.fl_str_mv Balogh, Gabriela Andrea
Mailo, Daniel
Nardi, Héctor
Corte, María Marta
Vincent, Esteban
Barutta, Elena
Lizarraga, Guillermo
Lizarraga, Pablo
Montero, Héctor
Gentili, Roberto
Mordoh, Jose
author Balogh, Gabriela Andrea
author_facet Balogh, Gabriela Andrea
Mailo, Daniel
Nardi, Héctor
Corte, María Marta
Vincent, Esteban
Barutta, Elena
Lizarraga, Guillermo
Lizarraga, Pablo
Montero, Héctor
Gentili, Roberto
Mordoh, Jose
author_role author
author2 Mailo, Daniel
Nardi, Héctor
Corte, María Marta
Vincent, Esteban
Barutta, Elena
Lizarraga, Guillermo
Lizarraga, Pablo
Montero, Héctor
Gentili, Roberto
Mordoh, Jose
author2_role author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv BREAST CANCER
P53 MUTATIONAL ANALYSIS
SEROLOGICAL DETECTION OF P53 MUTATIONS
topic BREAST CANCER
P53 MUTATIONAL ANALYSIS
SEROLOGICAL DETECTION OF P53 MUTATIONS
purl_subject.fl_str_mv https://purl.org/becyt/ford/1.6
https://purl.org/becyt/ford/1
dc.description.none.fl_txt_mv The aim of this study was to compare the sensitivity of the serological level of anti-p53 antibodies in breast cancer patients and to correlate its expression level with patient age, histological stage and grade of tumor differentiation. Total p53 protein expression (mutant and wild-type) was also determined in the breast cancer tissues using immunohistochemistry (IHC). The serological levels of mutant p53 expression were found to be age-dependent, reaching the highest level at 50 years of age. Faint or low detection was observed in patients ≤30 years of age. Anti-p53-antibodies were detected in patients ≤40 and ≥61 years of age. The serological levels of mutant p53 protein were highly detected in all stages of breast cancer, including the early stages. However, anti-p53 antibodies reached a high level of detection only in stage III breast carcinomas. No expression was found in patients with benign breast disease. The detection of p53 mutations was dependent on the grade of tumor differentiation, achieving the highest level in the poorly differentiated breast carcinomas. Results from IHC were highly correlated with serological p53 mutational analysis. Our findings indicate that mutant p53 in serum is a promising novel parameter for the evaluation of cellular biology and the prognosis of breast cancer from its early stages using blood samples. Anti-p53 antibodies were demonstrated to be less sensitive in this study. It is also possible to use the expression of mutant p53 protein as a molecular marker to differentiate benign breast disease from breast carcinoma prior to surgery.
Fil: Balogh, Gabriela Andrea. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Bahía Blanca. Centro de Recursos Naturales Renovables de la Zona Semiarida. Universidad Nacional del Sur. Centro de Recursos Naturales Renovables de la Zona Semiarida; Argentina
Fil: Mailo, Daniel. No especifíca;
Fil: Nardi, Héctor. No especifíca;
Fil: Corte, María Marta. No especifíca;
Fil: Vincent, Esteban. No especifíca;
Fil: Barutta, Elena. No especifíca;
Fil: Lizarraga, Guillermo. No especifíca;
Fil: Lizarraga, Pablo. No especifíca;
Fil: Montero, Héctor. No especifíca;
Fil: Gentili, Roberto. No especifíca;
Fil: Mordoh, Jose. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Pque. Centenario. Instituto de Investigaciones Bioquímicas de Buenos Aires. Fundación Instituto Leloir. Instituto de Investigaciones Bioquímicas de Buenos Aires; Argentina
description The aim of this study was to compare the sensitivity of the serological level of anti-p53 antibodies in breast cancer patients and to correlate its expression level with patient age, histological stage and grade of tumor differentiation. Total p53 protein expression (mutant and wild-type) was also determined in the breast cancer tissues using immunohistochemistry (IHC). The serological levels of mutant p53 expression were found to be age-dependent, reaching the highest level at 50 years of age. Faint or low detection was observed in patients ≤30 years of age. Anti-p53-antibodies were detected in patients ≤40 and ≥61 years of age. The serological levels of mutant p53 protein were highly detected in all stages of breast cancer, including the early stages. However, anti-p53 antibodies reached a high level of detection only in stage III breast carcinomas. No expression was found in patients with benign breast disease. The detection of p53 mutations was dependent on the grade of tumor differentiation, achieving the highest level in the poorly differentiated breast carcinomas. Results from IHC were highly correlated with serological p53 mutational analysis. Our findings indicate that mutant p53 in serum is a promising novel parameter for the evaluation of cellular biology and the prognosis of breast cancer from its early stages using blood samples. Anti-p53 antibodies were demonstrated to be less sensitive in this study. It is also possible to use the expression of mutant p53 protein as a molecular marker to differentiate benign breast disease from breast carcinoma prior to surgery.
publishDate 2010
dc.date.none.fl_str_mv 2010-03-01
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/16134
Balogh, Gabriela Andrea; Mailo, Daniel; Nardi, Héctor; Corte, María Marta; Vincent, Esteban; et al.; Serological levels of mutated p53 protein are highly detected at early stages in breast cancer patients; Spandidos Publ Ltd; Experimental and Therapeutic Medicine; 1; 2; 1-3-2010; 357-361
1792-0981
1792-1015
url http://hdl.handle.net/11336/16134
identifier_str_mv Balogh, Gabriela Andrea; Mailo, Daniel; Nardi, Héctor; Corte, María Marta; Vincent, Esteban; et al.; Serological levels of mutated p53 protein are highly detected at early stages in breast cancer patients; Spandidos Publ Ltd; Experimental and Therapeutic Medicine; 1; 2; 1-3-2010; 357-361
1792-0981
1792-1015
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/DOI:10.3892/etm_00000056
info:eu-repo/semantics/altIdentifier/url/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3445953/
info:eu-repo/semantics/altIdentifier/url/https://www.spandidos-publications.com/etm/1/2/357
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/msword
application/pdf
dc.publisher.none.fl_str_mv Spandidos Publ Ltd
publisher.none.fl_str_mv Spandidos Publ Ltd
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842981224888401920
score 12.48226

Publicaciones similares